SCHEDULE: Orbis, Allan Gray Disclose 5.5% Stake in CRISPR Therapeutics

Orbis Investment Management and Allan Gray Australia have jointly disclosed a 5.5% beneficial ownership stake in CRISPR Therapeutics AG common stock.

Summary

• Orbis Investment Management Ltd. and Allan Gray Australia Pty Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports an aggregate beneficial ownership of 4,982,085 shares of CRISPR Therapeutics AG Common Stock.
• This aggregate amount represents 5.5% of the class of securities.
• Orbis Investment Management Ltd. holds 4,974,125 shares with sole voting and dispositive power.
• Allan Gray Australia Pty Ltd. holds 7,960 shares with sole voting and dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a 5.5% beneficial ownership by two prominent investment management firms, Orbis and Allan Gray, suggests a positive long-term view on CRISPR Therapeutics AG. This institutional backing can be interpreted as a vote of confidence in the company's future prospects and technology.

Positives

• Two reputable financial institutions, Orbis Investment Management and Allan Gray Australia, have taken a significant combined stake of 5.5% in CRISPR Therapeutics AG.
• This indicates a vote of confidence from institutional investors in the company's long-term prospects and strategic direction.

Negatives

• No negative information regarding CRISPR Therapeutics AG's performance or operations is disclosed in this ownership filing.

Risks

• NA

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• The foreign regulatory scheme applicable to Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s).

Industry Context

This filing indicates that major global investment managers are allocating capital to the biotechnology sector, specifically to companies like CRISPR Therapeutics AG, which is at the forefront of gene-editing technology. Such institutional interest can signal perceived growth potential within the innovative healthcare and life sciences industries.

Stakeholder Impact

• Shareholders: The disclosure of significant institutional ownership may instill greater confidence in existing shareholders and attract new investors, potentially influencing stock valuation.
• Company Management: Increased institutional scrutiny and potential engagement from large shareholders.

Key Dates

Recommendation

The filing reveals that two significant institutional investors, Orbis Investment Management and Allan Gray Australia, have collectively acquired a 5.5% stake in CRISPR Therapeutics AG. While this indicates a vote of confidence from sophisticated investors and could be seen as a positive long-term signal, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data. Therefore, without additional fundamental analysis or new company-specific news, a "hold" recommendation is prudent, acknowledging the positive institutional interest while awaiting further catalysts or financial disclosures.

Keywords

CRISPR Therapeutics AG, Orbis Investment Management, Allan Gray Australia, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, gene editing